5th and 6th Sero Survey of Delhi: Vaccine Activated Antibodies Enhancement



Abstract Views
603

Downloads
393

Citations

Share

##plugins.themes.bootstrap3.article.sidebar##

Submitted Nov 23, 2021
Published Jan 28, 2022
10.24018/ejmed.2022.4.1.1152

Abstract viewed = 603 times

Table of Contents

##plugins.themes.bootstrap3.article.main##

The results of all six serosurveys of Delhi (India) have been analysed. The first serosurvey held in June-July 2020 found seroprevalence in 22.9% population. The second, third, and fourth survey conducted in August, September, and October registered 29.1%, 25.1%, and 25.5% seropositivity, respectively. The seroprevalence was increased to a larger extent of 56.1% in the fifth (January 2021) survey due to the accumulation of antibodies among the residents in three pandemic waves that hit the city in June, September, and November 2020. The last and the fourth bigger wave that hit the city in April 2021 caused almost all (97%) citizens to develop antibodies against the natural COVID-19 infection. The seroprevalence in women was marginally higher (90%) than in men (88%). The seroprevalence was highest (92%) among the individuals above 50 years of age followed by 18-49 years of age (90%) and 82% in below 18 years of age. The residents who were vaccinated with Covishield produced slightly higher antibodies (95%) than Covaxin (93%). In Delhi,one dose or two doses vaccination could increase seroprevalence to 95% that was the maximum which vaccination could generate. The unvaccinated population had seroprevalence of 85%. A maximum enhancement of 13% seroprevalence was recorded upon vaccination with one or two doses.

Keywords: Antibodies enhancement, COVID-19 vaccines, COVID-19 seroprevalence, Delhi serosurvey, herd immunity, SARS-CoV-2 spread

Downloads

Download data is not yet available.

References

  1. Covid-19 global death toll tops 5 million in under 2 years. [Internet] [cited November 1, 2021] The Times of India.
     Google Scholar
  2. Shervani Z, Bhardwaj D, Nikhat R, Ibbrahim A, Khan I, Qazi UY, et al. 4th National Sero Survey of India: Vaccine Generated Antibodies Enhancement, European Journal of Health and Medical Sciences. 2021 (in press).
     Google Scholar
  3. WHO raises alarm over fresh Covid surge in Europe: All you need to know. [Internet] [cited November 6, 2021] Hindustan Times.
     Google Scholar
  4. Global Covid-19 tally crosses 250 million: Report. [Internet] [cited November 9, 2021] Hindustan Times.
     Google Scholar
  5. Russia sees record daily Covid-19 cases despite paid holiday. [Internet] [cited November 6, 2021] Hindustan Times.
     Google Scholar
  6. New Zealand's daily coronavirus cases cross 200 for first time in pandemic. [Internet] [cited November 6, 2021] Reuters.
     Google Scholar
  7. At 10,929, India sees less than 11,000 fresh Covid-19 cases for 2nd time this week. [Internet] [cited November 6, 2021] Hindustan Times.
     Google Scholar
  8. Coronavirus (COVID-19)-Google News-India.
     Google Scholar
  9. India’s COVID-19 cases hit 9-month low. [Internet] [cited November 6, 2021] The Hindu.
     Google Scholar
  10. Covid-19:78% people received first dose of vaccine, 35% fully jabbed, says Mandaviya. [Internet] [cited November 1, 2021] Hindustan Times.
     Google Scholar
  11. Japan reports no COVID-related deaths for the first time in 15 months. [Internet] [cited November 7, 2021] The Japan Times.
     Google Scholar
  12. Britain approves Merck’s COVID-19 pill in world first. [Internet] [cited November 5, 2021] Reuters.
     Google Scholar
  13. Pfizer develops COVID-19 pill that cuts hospitalizations and deaths by 89%. [Internet] [cited November 5, 2021] The Japan Times.
     Google Scholar
  14. COVID-19 drugs will change the way we live with the virus. [Internet] [cited November 7, 2021] The Japan Times.
     Google Scholar
  15. Pfizer to seek OK for use of COVID-19 shot in children in Japan age 5 to 11. [Internet] [cited October 28, 2021] The Japan Times.
     Google Scholar
  16. Zydus jab cleared for kids to cost govt ₹265. [Internet] [cited November 9, 2021] Hindustan Times.
     Google Scholar
  17. UK allows early booking of booster shots to ramp up vaccine rollout. [Internet] [cited November 6, 2021] Hindustan Times.
     Google Scholar
  18. Belgium plans COVID-19 booster shot for all. [Internet] [cited November 10, 2021] Toronto Star.
     Google Scholar
  19. Japan Oks administration of Pfizer COVID-19 vaccine booster shots. [Internet] [cited November 10, 2021] The Japan Times.
     Google Scholar
  20. Pfizer vaccine’s protection wanes over time, and not because of Delta, study says, [Internet] [cited October 4, 2021] Los Angeles Times.
     Google Scholar
  21. Shervani Z, Bhardwaj D, Nikhat R. Dharavi Slums (Mumbai, India): The Petri Dish of COVID-19 Herd Immunity. European Journal of Medical and Health Sciences. 2021; 3(3): 38-41.
    DOI  |   Google Scholar
  22. Shervani Z. COVID-19 in Kerala: Health Index Theory. European Journal of Medical and Health Sciences. 2021; 3(2): 21-24.
    DOI  |   Google Scholar
  23. Shervani Z. COVID-19 in Kerala: The Dynamics of Spread and Health Index Theory. RAS Medical Science. 2021; 1(2): 1-3.
    DOI  |   Google Scholar
  24. Shervani Z, Khan I, Siddiqui NY, Khan T, Qazi UY.Viability of SARS-CoV-2 and Sanitization Methods. European Journal of Medical and Health Sciences. 2021; 3(1): 22-27.
    DOI  |   Google Scholar
  25. Shervani Z, Khan I, Siddiqui NY, Khan T, Qazi UY. Risk of SARS-CoV-2 Transmission from Humans to Pets and Vice Versa. European Journal of Medical and Health Sciences. 2021; 3(1): 34-38.
    DOI  |   Google Scholar
  26. Shervani Z, Khan I, Qazi UY. Sars-cov-2 delayed Tokyo 2020 Olympics: Very recent advances in covid-19 detection, treatment, and vaccine development useful conducting the games in 2021. Advances in Infectious Diseases. 2020; 10(3): 56-66.
    DOI  |   Google Scholar
  27. Shervani Z, Khan I, Qazi UY. COVID-19 vaccine. Advances in Infectious Diseases. 2020; 10(3): 195-210.
    DOI  |   Google Scholar
  28. Shervani Z, Khan I, Khan T, Qazi UY. World’s fastest supercomputer picks COVID-19 drug. Advances in Infectious Diseases. 2020; 10(3): 211-225.
    DOI  |   Google Scholar
  29. Sharma N, Sharma P, Basu S, Bakshi R, Gupta E, Agarwal R, et al. Second wave of the Covid-19 pandemic in Delhi, India: high seroprevalence not a deterrent? Cureus. 2021; 13(10).
    DOI  |   Google Scholar
  30. https://www.indiaonlinepages.com/population/delhi-population.html.
     Google Scholar
  31. Over 50% exposer to Sars-Cov-2 in 10 of 11 city districts: serosurvey in Delhi. [Internet] [cited February 3, 2021] Hindustan Times.
     Google Scholar
  32. Delhi 6th Sero-survey: 97% of People Have COVID Antibodies, Says Health Minister. [Internet] [cited October 28, 2021] The Quint
     Google Scholar
  33. Delhi 6th sero-survey: More than 90% have antibodies. [Internet] [cited October 27, 2021] The Hindu.
     Google Scholar
  34. Herd Immunity for Delhi? As Sixth Sero Survey Finds Over 90% Have Antibodies, Here`s What it Means. [Internet] [cited October 28, 2021] News 18.
     Google Scholar
  35. Covid antibodies found in 97% of Delhi residents. [Internet] [cited October 29, 2021] Times of India.
     Google Scholar
  36. th Delhi sero survey shows 97% prevalence of antibodies. [Internet] [cited November 13, 2021] Hindustan Times.
     Google Scholar


Most read articles by the same author(s)

1 2 > >>